US3902497A - Body absorbable sponge and method of making - Google Patents

Body absorbable sponge and method of making Download PDF

Info

Publication number
US3902497A
US3902497A US454353A US45435374A US3902497A US 3902497 A US3902497 A US 3902497A US 454353 A US454353 A US 454353A US 45435374 A US45435374 A US 45435374A US 3902497 A US3902497 A US 3902497A
Authority
US
United States
Prior art keywords
tissue
sponge
absorbable
polymer
absorbable polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US454353A
Inventor
Donald James Casey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Priority to US454353A priority Critical patent/US3902497A/en
Priority to AR257766A priority patent/AR205109A1/en
Priority to CA219,627A priority patent/CA1045548A/en
Priority to GB6053/75A priority patent/GB1490425A/en
Priority to AU78222/75A priority patent/AU496185B2/en
Priority to IT8230/75A priority patent/IT1050278B/en
Priority to BR1268/75A priority patent/BR7531268A/en
Priority to FR7509310A priority patent/FR2265412B1/fr
Priority to DE19752513159 priority patent/DE2513159A1/en
Priority to JP50035036A priority patent/JPS51116079A/en
Application granted granted Critical
Publication of US3902497A publication Critical patent/US3902497A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/64Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/425Porous materials, e.g. foams or sponges
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/04Materials for stopping bleeding

Definitions

  • ABSTRACT PP A conformable tissue absorbable surgical sponge is formed by dissolving a tissue absorbable polymer in 52 US. Cl 128/296; 260/25 E; 128/325 hexaflumoisopropyl alcohol or hexafluoroacetone [51] Int.
  • the sponge may be used to absorb blood or other liq- [56] References Cited uids during a surgical procedure or may be used as a UNITED STATES PATENTS hemostat and allowed to remam 1n aclos ed wound wlth the polymer belng absorbed by 11v1ng t1ssue. 3,297,033 l/l967 Schmitt et a1 Vietnamese 128/335.5 3,666,750 5/1972 Briskin et a1 128/325 6 Claims, 6 Drawing Figures PATENTEU SEP 2 YS SHEET 1 BF 3 PATENTS] SE?
  • Surgical sponges find many uses in which an absor bent sponge is desirable to soak up blood, serum, or other body fluids, which sponges are removed and discarded.
  • Cotton gauze sponges are used in many instances. When used internally, there is a problem of part of the sponge coming off and leaving threads or larger portions of the sponge in the wound. Concern over leaving a sponge in a patient complicates operating room practice and involves extremely rigorous counting procedures to insure that no sponge is accidentally left in a closed wound.
  • sutures and tieoffs can be used. In some instances it is highly desirable that additional methods of controlling bleeding be made available. More or less successful efforts have been made to se cure conformable hemostats which can be used to control bleeding and then left in the wound. The problem is well recognized and more acceptable devices are in constant demand.
  • U.S. Pat. No. 3,297,033, Schmitt and Polistina, Jan. 10, 1967, SURGICAL SUTURES discloses polyhydroxyacetic ester absorbable sutures.
  • the material is also called polyglycolic acid, and is disclosed as permitting small quantities of comonomers to be present, such as dl-lactic acid, its optically active forms, homologs and analogs.
  • a small quantity is recognized by the art as up to as shown by U.S. Pat. No. 2,668,162, Lowe, Feb. 2, 1954, PREPARATION OF HIGH MO LECULAR WEIGHT POLYHYDROXY-ACETIC ES- TER.
  • U.S. Pat. No. 3,783,093, Gallacher, Jan. 1, 1974, F1- BROUS POLYETHYLENE MATERIALS discloses a fibrillated material, mentioning poly(glycolic acid) among others, in which one resin is mixed and fibrillated with another, and one resin leached out to give the product, a web of oriented, interconnected direc tional fiber-like strands, membranes, ribbons, branched ribbons and fibrils. These can be used as bandages and for other medicalpurposes;
  • Example 15 shows 25 parts of poly(glycolic acid) and 75 parts of poly-(methyl methacrylate) leached with acetone.
  • an oxidized regenerated cellulose is available, as in a gelatin foam distributed in sheet form. Both of these are absorbable in tissues. Under some conditions, the gelatin foam causes bile cysts. It is desirably wetted with saline at the time of use.
  • a hemostat can be made by dissolving a tissue absorbable polymer in the very powerful solvents hexafluoroisopropyl alcohol or hexafluoroacetone sesquihydrate, preferably filtering the solution, freezing, and subliming off the solvent, yielding a sponge which is readily conformable to wound to pography, highly absorbent and versatile. It may be used in procedures in which the foam sponge is to be left in the wound and absorbed by body tissues and also sees great acceptance in sponges which are used to absorb blood, serum or other liquids with the sponge being removed and discarded. Because there is the ever present risk of part of the sponge falling off and being left in the wound or through inadvertence being closed in the wound, it is desirable that tissue absorbable sponges be used for general surgical use, wherever tissue may grow into the sponge.
  • a sponge should have high absorptive capacity, should absorb fluids, particularly blood, rapidly, should be strong enough to be readily handled in surgical procedures, and conformable enough that it fits into whatever topography and space that is available, and be soft enough so that it does not injure sensitive tissues.
  • the absorbability of the present sponges by the body reduces the risks from the inadvertent enclosure of portions of a hemostatic sponge in living tissue-because such portions are absorbed and removed by the tissue itself.
  • freeze drying is a well-known technique, it is usually drying of water from frozen compositions in which water is to be removed by sublimation; and the product is usually rather brittle and friable so that it is not readily conformable, and is easily broken.
  • the solvent which is removed by sublimation, is hexafluoroisopropyl alcohol or hexafluoroacetone sesquihydrate or a mixture of the two.
  • the residual foam is softer and more conformable than products usually secured from aqueous systems. It is, of course, not possible to use an aqueous system with the tissue absorbable polymer of this invention.
  • the polymers are not water soluble.
  • the absorbable sponge structure is more readily freed from other components than in a leach technique using a mixture of polymers in which one polymer is leached out, thus requiring elimination of not only the leached polymer, but also the leaching solvent.
  • freeze-drying sometimes implies an aqueous system
  • sublimation-drying is used in many places herein to accentuate that it is an organic solvent system which is being sublimed so that it could be called solvent-sublimation for sponge manufacture.
  • Products prepared in an aqueous system are generally friable. Using hexafluoroisopropyl alcohol or hexafiuoroacetone sesquihydrate as a solvent for polyglycolic acid, and other tissue absorbable compositions, yields a product which is readily flexible and tissue conformable.
  • homopolymeric polyglycolic acid is currently being used in sutures, has met with the approval of many government agencies in many countries, is commercially available, and is familiar to chemists, the present invention is primarily described in detail in relation to homopolymeric polyglycolic acid.
  • Polyglycolic acid containing up to of other units, such as lactic acid units, is considered within the term polyglycolic acid as used hereien unless specified as homopolymeric.
  • Other materials such as poly(N-acetyl-D-glucosamine) and polymers of 3-methyl-l ,4- dioxane-2,5-dione may be used.
  • Poly(N-acetyl-D- glycosamine) is described in US. Ser. No. 441,717, filed on or about Feb. I 1, 1974, Richard Carl Capozza, POLY( N-ACETYL-D-G LUCOSAMINE) PROD- UCTS.
  • the present invention is particularly useful with tissue absorbable polymers which are insoluble in common organic solvents.
  • the foam should conform to the surface of the tissue. Conformation comprises an assessment of the suppleness, resiliency, and foams ability to mimic the topography of the wound in such a fashion that there is a minimum gap between the tissue and the foam which minimizes air gaps and pools of liquid. If pools of liquid build up, whether of serum or blood, such pools may become sites for the growth of undesirable microorganisms, particularly for external dressings. If the foam conforms adequately to the surface of the wound, the bodys own defense mechanisms are effective up to the zone of contact with the foam, and bacterial contamination is minimized.
  • FIG. 1 shows a scanning electron microscope photomicrograph at 50 diameters magnification of the surface of a frozen and dried sample produced in accordance with Example 1.
  • FIG. 2 is a portion of the same structure at 300 diameters magnification.
  • FIG. 3 is a photomicrograph similar to FIG. 1 at 50 diameters magnification of the reverse side of the same structure.
  • FIG. 4 is the same surface as FIG. 3, but at 300 diameters magnification.
  • FIG. 5 is a razor cut cross section of the same sample as FIG. 1 at 50 diameters magnification.
  • FIG. 6 is the same razor cut cross section as FIG. 5 at 300 diameters magnification.
  • a scale on each photomicrograph shows relative sizes.
  • the polyglycolic acid forms ribbons and shows a fibrillar structure with the ribbons, sheets and fibers interconnected with many of the ribbons having considerable greater width than thickness.
  • the thickness in general is within the range of from about I to 5 microns.
  • the dried structure is spongy in character but resilient so as to be conformable to a wound surface and is not friable and brittle as are most frozen-dried solids in which the solids are dried from an aqueous system.
  • EXAMPLE 1 Polyglycolic Acid in Hexafluoroisopropyl Alcohol 10.3 Grams of low crystallinity homopolymeric polyglycolic acid was dissolved in ISO milliliters of hexa fluoroisopropyl alcohol by stirring at 36 to 37C. until solution resulted (about 3 hours). The resulting solution was freed from dust and inadvertent trace contaminants by filtration through a sintered glass filter, and transferred to a flat bottom dish. An additional milliliters of hexafluoroisopropyl alcohol was used to dilute the solution to about 4% concentration (wt/vol. The dish was surrounded by a solid carbon dioxideacetone mixture until the solution was solidly frozen.
  • the solvent free foam was placed in strippable packages, sterilized with 12% ethylene oxide in dichlorodifluoromethane and thus kept dry and sterile until time of use.
  • the foam As a hemostatic sponge, the foam conforms well to a wound and arrests the flow of blood immediately. The initial arresting of bleeding is largely mechanical. Blood then coagulates in the sponge. which both arrests the further flow of blood, and tends to hold the sponge in position.
  • the slices can be cut or broken into a size and shape adapted to cover a particular wound.
  • the foam is usable in a wound which is to be closed, such as, for example, on the surface of the liver with the foam being closed into the abdominal cavity, or it may be used on the surface of the body as protection, and allowed to remain until the wound is healed.
  • the foam may be used as an absorbent to absorb blood and other fluids at the site of a wound to dry the wound for subsequent suturing or closing as required by a particular surgical procedure.
  • the foam In test animals on sacrifice, the foam is found to be essentially absorbed within 90 days.
  • EXAMPLE 2 Polyglycolic Acid in Hexafluoroacetone Sesquihydrate 1.9 Grams of homopolymeric polyglycolic acid was dissolved in 45 ml. of hexafluoroacetone sesquihydrate by heating the mixture of 50C. with stirring for three hours, yielding a solution having a concentration of approximately 4.2% (wt./vol.). The solution was filtered through a sintered glass filter and transferred to a flat dish and the clear amber solution was set in a solid carbon dioxide-acetone mixture for about an hour until frozen completely solid.
  • the dish was then placed in a vacuum chamber and the hexafluoroacetone sesquihydrate was sublimed off at a reduced pressure of about 1 torr. After about 24 hours, the spongelike foam obtained was removed, sliced into Va inch thick slices, and again placed in a closed chamber evacuated at l torr. with heating to about 80C. for several days. The product was then essentially free from solvent. The slices were sealed in strippable packages, sterilized with ethylene oxide and kept dry until time for use, using techniques routinely employed for polyglycolic acid sutures.
  • the sponge was an effective absorbent for blood and served as an effective hemostat on wound surfaces.
  • the polymers herein described are named from the monomer or monomers from which the polymers can be considered as formed.
  • the key polymer, polyglycolic acid is so named whether made from glycolic acid or glycolide, even though the units in the chain could properly be described as glycolyl linkages.
  • such nomenclature is regarded as historically the most significant and the least ambiguous.
  • a method of making a hemostat comprising dissolving a tissue-absorbable polymer in hexafluoroisopropyl alcohol or hexafluoroacetone sesquihydrate, filtering to remove any insoluble contaminants, freezing the solution and subliming off the solvent, whereby an absorbable sponge structure is formed, which is essentially non-directional and is readily conformable to tissue surfaces.
  • tissue absorbable polymer comprises glycolic acid, having such a high glycolic acid content that it is insoluble in common organic solvents.
  • tissue absorbable polymer is homopolymeric polyglycolic acid.
  • a hemostatic surgical sponge of a tissue absorbable polymer comprising glycolic acid, having at least of the monomer units of glycolic acid, whereby it is insoluble in common organic solvents, in the form of a sheet having interconnected ribbons and ligaments of a single polymer which is essentially non-directional having a network of connecting elements, and which is sufficiently flexible to be readily conformable to a wound surface.
  • tissue absorbable polymer is homopolymeric polyglycolic acid.

Abstract

A conformable tissue absorbable surgical sponge is formed by dissolving a tissue absorbable polymer in hexafluoroisopropyl alcohol or hexafluoroacetone sesquihydrate, filtering, freezing and subliming off the solvent to give a tissue conformable flexible sponge which rapidly absorbs blood and other body fluids. The sponge may be used to absorb blood or other liquids during a surgical procedure or may be used as a hemostat and allowed to remain in a closed wound with the polymer being absorbed by living tissue.

Description

United States Patent [1 1 Casey Se t. 2, 1975 [54] BODY ABSORBABLE SPONGE AND 3,705,585 12 1972 Saffro 128/325 METHOD OF MAKING 3,772,136 11/1973 Workman 128/156 3,801,675 4/1974 Russell 128/296 Inventor: Donald James y, g fi 3,825,007 7/1974 Rand 128/296 Conn.
[73] Assignee: American Cyanamid Company, Primary Examiner Lawrence Trapp Stamford Conn Attorney, Agent, or Firm-Samuel Branch Walker [22] Filed: Mar. 25, 1974 [57] ABSTRACT PP A conformable tissue absorbable surgical sponge is formed by dissolving a tissue absorbable polymer in 52 US. Cl 128/296; 260/25 E; 128/325 hexaflumoisopropyl alcohol or hexafluoroacetone [51] Int. 2 A61F 13/00 quihydrate, filtering, freezing and subliming off the [58] Field 61 Search 128/155-157, Solvent to give a Issue conformable flexlble Sponge 2 /290 29 325 334 335 5; E which rapidly absorbs blOOd and Oth6l' body fluids.
The sponge may be used to absorb blood or other liq- [56] References Cited uids during a surgical procedure or may be used as a UNITED STATES PATENTS hemostat and allowed to remam 1n aclos ed wound wlth the polymer belng absorbed by 11v1ng t1ssue. 3,297,033 l/l967 Schmitt et a1..... 128/335.5 3,666,750 5/1972 Briskin et a1 128/325 6 Claims, 6 Drawing Figures PATENTEU SEP 2 YS SHEET 1 BF 3 PATENTS] SE? 2 i 75 SHEET 2 UP 3 BODY ABSORBABLE SPONGE AND METHOD OF MAKING BACKGROUND OF THE INVENTION Surgical sponges find many uses in which an absor bent sponge is desirable to soak up blood, serum, or other body fluids, which sponges are removed and discarded. Cotton gauze sponges are used in many instances. When used internally, there is a problem of part of the sponge coming off and leaving threads or larger portions of the sponge in the wound. Concern over leaving a sponge in a patient complicates operating room practice and involves extremely rigorous counting procedures to insure that no sponge is accidentally left in a closed wound.
In many surgical procedures requiring a hemostat to control bleeding, sutures and tieoffs can be used. In some instances it is highly desirable that additional methods of controlling bleeding be made available. More or less successful efforts have been made to se cure conformable hemostats which can be used to control bleeding and then left in the wound. The problem is well recognized and more acceptable devices are in constant demand.
DESCRIPTION OF THE PRIOR ART The use of polyglycolic acid is disclosed in a series of patents and applications to Schmitt, et a1:
U.S. Pat. No. 3,297,033, Schmitt and Polistina, Jan. 10, 1967, SURGICAL SUTURES, discloses polyhydroxyacetic ester absorbable sutures. The material is also called polyglycolic acid, and is disclosed as permitting small quantities of comonomers to be present, such as dl-lactic acid, its optically active forms, homologs and analogs. A small quantity is recognized by the art as up to as shown by U.S. Pat. No. 2,668,162, Lowe, Feb. 2, 1954, PREPARATION OF HIGH MO LECULAR WEIGHT POLYHYDROXY-ACETIC ES- TER. I
U.S. Pat. No. 3,463,158, Schmitt and Polistina, Aug. 26, 1969, POLYGLYCOLIC ACID PROSTHETIC DEVICES, discloses surgical uses of polyglycolic acid, and incorporates definitions of some terms.
U.S. Pat. No. 3,620,218, Schmitt and Polistina, Nov. 16, 1971, CYLINDRICAL PROSTHETIC DEVICES OF POLYGLYCOLIC ACID, lists many uses of polyglycolic acid.
U.S. Pat. No. 3,736,646, Schmitt and Epstein, June 5, 1973, METHOD OF ATIACHING SURGICAL NEEDLES TO MULTIFILAMENT POLYGLYCOLIC ACID ABSORBABLE SUTURES, discloses surgical elements of a copolymer containing from 15 to 85 mol percent glycolic acid and 85 to 15 mol percent lactic acid.
U.S. Pat. No. 3,739,773, Schmitt and Polistina, June 19, 1973, POLYGLYCOLIC ACID PROSTHETIC DEVICES, claims particularly bone pins, plates, nails and screws of polyglycolic acid.
U.S. application Ser. No. 365,656, Schmitt and Polistina, May 31, 1973, SURGICAL DRESSINGS OF AB- SORBABLE POLYMERS now U.S. Pat. No. 3,875,937, discloses additional subject matter on surgical dressings of polyglycolic acid.
U.S. Pat. No. 3,739,773, supra, lists a number of U.S. patents on methods for preparing polyglycolic acid and starting materials therefor.
In U.S. Pat. No. 3,620,218, supra, in Column 2 are listed a number of medical uses of polyglycolic acids, including in Column 2; line 52, knitted or woven fibril lar products, including velours, and mentioning specifically in line 53, burn dressings; line 57, felt or sponge for liver hemostasis; line 63, foam as absorbable prosthesis; and in lines 74 and 75, burndressings (in combination withother polymeric films).
U.S. Pat. No. 3,737,440, Schmitt and Bailey, June 5, 1973, POLYGLYCOLIC ACID IN SOLUTIONS, discloses solutions of polyglycolic acid in hexafluoroisopropyl alcohol and hexafluoroacetone sesquihydrate, as well as wet and dry spinning of filaments and casting of films using these solutions.
U.S. Pat. No. 3,783,093, Gallacher, Jan. 1, 1974, F1- BROUS POLYETHYLENE MATERIALS, discloses a fibrillated material, mentioning poly(glycolic acid) among others, in which one resin is mixed and fibrillated with another, and one resin leached out to give the product, a web of oriented, interconnected direc tional fiber-like strands, membranes, ribbons, branched ribbons and fibrils. These can be used as bandages and for other medicalpurposes; Example 15 shows 25 parts of poly(glycolic acid) and 75 parts of poly-(methyl methacrylate) leached with acetone.
U.S. Pat. No. 2,899,362, Sieger, Valentine, and Weidenheimer, Aug. 1 l, 1959, HEMOSTATIC SPONGES AND METHOD OF PREPARING SAME, discloses a whipped starch-gelatin mixture which is aerated and dried to form a sponge which may be used for hemostatic purposes.
U.S. Pat. No. 3,653,383, Wise, Apr. 4, 1972, ALGIN SPONGE AND PROCESS THEREFOR, discloses algin sponges made by freeze-drying aqueous alginate dispersions or gels which can be used for burn dressings, and other surgical purposes. The product after use is water-disintegrative.
Commercially, an oxidized regenerated cellulose is available, as in a gelatin foam distributed in sheet form. Both of these are absorbable in tissues. Under some conditions, the gelatin foam causes bile cysts. It is desirably wetted with saline at the time of use.
The complete disclosures of the above patents and articles are hereby herein incorporated by this reference thereto.
The use of gauzes, felts, and knitted fabrics as a wound dressing is quite conventional. The use of collagenous products as a sponge or pad has been diclosed. The requirements for surgical hemostats are varied and more satisfactory hemostats than presently available are constantly in demand.
SUMMARY OF THE INVENTION It has now been found that a hemostat can be made by dissolving a tissue absorbable polymer in the very powerful solvents hexafluoroisopropyl alcohol or hexafluoroacetone sesquihydrate, preferably filtering the solution, freezing, and subliming off the solvent, yielding a sponge which is readily conformable to wound to pography, highly absorbent and versatile. It may be used in procedures in which the foam sponge is to be left in the wound and absorbed by body tissues and also sees great acceptance in sponges which are used to absorb blood, serum or other liquids with the sponge being removed and discarded. Because there is the ever present risk of part of the sponge falling off and being left in the wound or through inadvertence being closed in the wound, it is desirable that tissue absorbable sponges be used for general surgical use, wherever tissue may grow into the sponge.
A sponge should have high absorptive capacity, should absorb fluids, particularly blood, rapidly, should be strong enough to be readily handled in surgical procedures, and conformable enough that it fits into whatever topography and space that is available, and be soft enough so that it does not injure sensitive tissues.
The absorbability of the present sponges by the body reduces the risks from the inadvertent enclosure of portions of a hemostatic sponge in living tissue-because such portions are absorbed and removed by the tissue itself.
Although freeze drying is a well-known technique, it is usually drying of water from frozen compositions in which water is to be removed by sublimation; and the product is usually rather brittle and friable so that it is not readily conformable, and is easily broken.
Here the solvent, which is removed by sublimation, is hexafluoroisopropyl alcohol or hexafluoroacetone sesquihydrate or a mixture of the two. The residual foam is softer and more conformable than products usually secured from aqueous systems. It is, of course, not possible to use an aqueous system with the tissue absorbable polymer of this invention. The polymers are not water soluble.
Because the solvent is volatile, and is sublimed to remove the major portion, and the resulting cake is dried to remove the small remaining portion, the absorbable sponge structure is more readily freed from other components than in a leach technique using a mixture of polymers in which one polymer is leached out, thus requiring elimination of not only the leached polymer, but also the leaching solvent.
Because the term freeze-drying sometimes implies an aqueous system, the term sublimation-drying is used in many places herein to accentuate that it is an organic solvent system which is being sublimed so that it could be called solvent-sublimation for sponge manufacture. Products prepared in an aqueous system are generally friable. Using hexafluoroisopropyl alcohol or hexafiuoroacetone sesquihydrate as a solvent for polyglycolic acid, and other tissue absorbable compositions, yields a product which is readily flexible and tissue conformable.
Because homopolymeric polyglycolic acid is currently being used in sutures, has met with the approval of many government agencies in many countries, is commercially available, and is familiar to chemists, the present invention is primarily described in detail in relation to homopolymeric polyglycolic acid.
Polyglycolic acid containing up to of other units, such as lactic acid units, is considered within the term polyglycolic acid as used hereien unless specified as homopolymeric. Other materials such as poly(N-acetyl-D-glucosamine) and polymers of 3-methyl-l ,4- dioxane-2,5-dione may be used. Poly(N-acetyl-D- glycosamine) is described in US. Ser. No. 441,717, filed on or about Feb. I 1, 1974, Richard Carl Capozza, POLY( N-ACETYL-D-G LUCOSAMINE) PROD- UCTS.
The present invention is particularly useful with tissue absorbable polymers which are insoluble in common organic solvents.
The foam should conform to the surface of the tissue. Conformation comprises an assessment of the suppleness, resiliency, and foams ability to mimic the topography of the wound in such a fashion that there is a minimum gap between the tissue and the foam which minimizes air gaps and pools of liquid. If pools of liquid build up, whether of serum or blood, such pools may become sites for the growth of undesirable microorganisms, particularly for external dressings. If the foam conforms adequately to the surface of the wound, the bodys own defense mechanisms are effective up to the zone of contact with the foam, and bacterial contamination is minimized.
DRAWINGS FIG. 1 shows a scanning electron microscope photomicrograph at 50 diameters magnification of the surface of a frozen and dried sample produced in accordance with Example 1.
FIG. 2 is a portion of the same structure at 300 diameters magnification.
FIG. 3 is a photomicrograph similar to FIG. 1 at 50 diameters magnification of the reverse side of the same structure.
FIG. 4 is the same surface as FIG. 3, but at 300 diameters magnification.
FIG. 5 is a razor cut cross section of the same sample as FIG. 1 at 50 diameters magnification.
FIG. 6 is the same razor cut cross section as FIG. 5 at 300 diameters magnification.
A scale on each photomicrograph shows relative sizes.
As exemplified by the drawing, the polyglycolic acid forms ribbons and shows a fibrillar structure with the ribbons, sheets and fibers interconnected with many of the ribbons having considerable greater width than thickness. The thickness in general is within the range of from about I to 5 microns. The dried structure is spongy in character but resilient so as to be conformable to a wound surface and is not friable and brittle as are most frozen-dried solids in which the solids are dried from an aqueous system.
EXAMPLE 1 Polyglycolic Acid in Hexafluoroisopropyl Alcohol 10.3 Grams of low crystallinity homopolymeric polyglycolic acid was dissolved in ISO milliliters of hexa fluoroisopropyl alcohol by stirring at 36 to 37C. until solution resulted (about 3 hours). The resulting solution was freed from dust and inadvertent trace contaminants by filtration through a sintered glass filter, and transferred to a flat bottom dish. An additional milliliters of hexafluoroisopropyl alcohol was used to dilute the solution to about 4% concentration (wt/vol. The dish was surrounded by a solid carbon dioxideacetone mixture until the solution was solidly frozen. The dish in its frozen condition was placed in a resin kettle which was sealed and connected to a high vacuum system. Vacuum was maintained using a solid carbon dioxide acetone cooled trap to protect the vacuum pump for 16 hours during which time the kettle was allowed to warm up with the hexafluoroisopropyl alcohol being maintained in its solid state by evaporative cooling, and with no meltbacks. After the thus formed foam had only a few percent residual hexafluoroisopropyl alcohol therein, the foam cake was removed, cut into /=r inch thick slices and further subjected to vacuum and heat at about 55C. until substantially all of the hexafluoroisopropyl alcohol was removed.
The solvent free foam was placed in strippable packages, sterilized with 12% ethylene oxide in dichlorodifluoromethane and thus kept dry and sterile until time of use.
As a hemostatic sponge, the foam conforms well to a wound and arrests the flow of blood immediately. The initial arresting of bleeding is largely mechanical. Blood then coagulates in the sponge. which both arrests the further flow of blood, and tends to hold the sponge in position. The slices can be cut or broken into a size and shape adapted to cover a particular wound. The foam is usable in a wound which is to be closed, such as, for example, on the surface of the liver with the foam being closed into the abdominal cavity, or it may be used on the surface of the body as protection, and allowed to remain until the wound is healed. The foam may be used as an absorbent to absorb blood and other fluids at the site of a wound to dry the wound for subsequent suturing or closing as required by a particular surgical procedure.
In test animals on sacrifice, the foam is found to be essentially absorbed within 90 days.
EXAMPLE 2 Polyglycolic Acid in Hexafluoroacetone Sesquihydrate 1.9 Grams of homopolymeric polyglycolic acid was dissolved in 45 ml. of hexafluoroacetone sesquihydrate by heating the mixture of 50C. with stirring for three hours, yielding a solution having a concentration of approximately 4.2% (wt./vol.). The solution was filtered through a sintered glass filter and transferred to a flat dish and the clear amber solution was set in a solid carbon dioxide-acetone mixture for about an hour until frozen completely solid.
The dish was then placed in a vacuum chamber and the hexafluoroacetone sesquihydrate was sublimed off at a reduced pressure of about 1 torr. After about 24 hours, the spongelike foam obtained was removed, sliced into Va inch thick slices, and again placed in a closed chamber evacuated at l torr. with heating to about 80C. for several days. The product was then essentially free from solvent. The slices were sealed in strippable packages, sterilized with ethylene oxide and kept dry until time for use, using techniques routinely employed for polyglycolic acid sutures.
The sponge was an effective absorbent for blood and served as an effective hemostat on wound surfaces.
in accordance with conventional usage in the polymer field, the polymers herein described are named from the monomer or monomers from which the polymers can be considered as formed. For instance, the key polymer, polyglycolic acid, is so named whether made from glycolic acid or glycolide, even though the units in the chain could properly be described as glycolyl linkages. Particularly, when considered with the incorporated cited prior art, and commercial usage in the field, such nomenclature is regarded as historically the most significant and the least ambiguous.
I claim:
1. A method of making a hemostat comprising dissolving a tissue-absorbable polymer in hexafluoroisopropyl alcohol or hexafluoroacetone sesquihydrate, filtering to remove any insoluble contaminants, freezing the solution and subliming off the solvent, whereby an absorbable sponge structure is formed, which is essentially non-directional and is readily conformable to tissue surfaces.
2. The method of claim 1 in which the tissue absorbable polymer comprises glycolic acid, having such a high glycolic acid content that it is insoluble in common organic solvents.
3. The method of claim 2 in which the tissue absorbable polymer is homopolymeric polyglycolic acid.
4. A hemostatic surgical sponge of a tissue absorbable polymer comprising glycolic acid, having at least of the monomer units of glycolic acid, whereby it is insoluble in common organic solvents, in the form of a sheet having interconnected ribbons and ligaments of a single polymer which is essentially non-directional having a network of connecting elements, and which is sufficiently flexible to be readily conformable to a wound surface.
5. The sponge of claim 4 in which the tissue absorbable polymer is homopolymeric polyglycolic acid.
6. A hemostatic surgical sponge of a tissue absorbable polymer in the form of a sheet having interconnected ribbons and ligaments of a single polymer which is essentially non-directional having a network of connecting elements, and which is sufficiently flexible to be readily conformable to a wound surface; made by the process of dissolving a tissue-absorbable polymer in hexafluoroisopropyl alcohol or hexafluoroacetone sesquihydrate, filtering to remove any insoluble contaminants, freezing the solution and subliming off the solvent, whereby an absorbable sponge structure is formed, which is essentially non-directional and is readily conformable to tissue surfaces.

Claims (6)

1. A METHOD OF MAKING A HEMOSTAT COMPRISING DISSOLVING A TISSUE-ABSORBABLE POLYMER IN HEXAFLUOROISOPROPYL ALCOHOL OR HEXAFLUOROACETONE SESQUIHYDRATE, FILTERING TO REMOVE ANY INSOLUBLE CONTAMINANT, FREEZING THE SOLUTION AND SUBLIMING OFF THE SOLVENT, WHEREBY AN ABSORBABLE SPONGE STRUCTURE IS FORMED, WHICH IS ESSENTIALLY NON-DIRECTIONAL AND IS READILY CONFORMABLE TO TISSUE SURFACES.
2. The method of claim 1 in which the tissue absorbable polymer comprises glycolic acid, having such a high glycolic acid content that it is insoluble in common organic solvents.
3. The method of claim 2 in which the tissue absorbable polymer is homopolymeric polyglycolic acid.
4. A hemostatic surgical sponge of a tissue absorbable polymer comprising glycolic acid, having at least 85% of the monomer units of glycolic acid, whereby it is insoluble in common organic solvents, in the form of a sheet having interconnected ribbons and ligaments of a single polymer which is essentially non-directional having a network of connecting elements, and which is sufficiently flexible to be readily conformable to a wound surface.
5. The sponge of claim 4 in which the tissue absorbable polymer is homopolymeric polyglycolic acid.
6. A hemostatic surgical sponge of a tissue absorbable polymer in the form of a sheet having interconnected ribbons and ligaments of a single polymer which is essentially non-directional having a network of connecting elements, and which is sufficiently flexible to be readily conformable to a wound surface; made by the process of dissolving a tissue-absorbable polymer in hexafluoroisopropyl alcohol or hexafluoroacetone sesquihydrate, filtering to remove any insoluble contaminants, freezing the solution and subliming off the solvent, whereby an absorbable sponge structure is formed, which is essentially non-directional and is readily conformable to tissue surfaces.
US454353A 1974-03-25 1974-03-25 Body absorbable sponge and method of making Expired - Lifetime US3902497A (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US454353A US3902497A (en) 1974-03-25 1974-03-25 Body absorbable sponge and method of making
AR257766A AR205109A1 (en) 1974-03-25 1975-01-01 A METHOD OF PREPARING A HEMOSTAT AND THE RESULTING HEMOSTAT
CA219,627A CA1045548A (en) 1974-03-25 1975-02-07 Tissue absorbable polymer sponge
GB6053/75A GB1490425A (en) 1974-03-25 1975-02-12 Surgical sponge
AU78222/75A AU496185B2 (en) 1974-03-25 1975-02-14 Sponge
IT8230/75A IT1050278B (en) 1974-03-25 1975-02-18 PROCEDURE FOR THE PRODUCTION OF HEMOSTATIC SPONGES AND PRODUCT OBTAINED
BR1268/75A BR7531268A (en) 1974-03-25 1975-03-04 PROCESS FOR THE PRODUCTION OF A HEMOSTAT AND HEMOSTATIC SURGICAL SPONGE
FR7509310A FR2265412B1 (en) 1974-03-25 1975-03-25
DE19752513159 DE2513159A1 (en) 1974-03-25 1975-03-25 HEMISTIC SPOOLS AND METHOD FOR PRODUCING THEM
JP50035036A JPS51116079A (en) 1974-03-25 1975-03-25 Tissueeabsorptive sponge and method of manufacturing same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US454353A US3902497A (en) 1974-03-25 1974-03-25 Body absorbable sponge and method of making

Publications (1)

Publication Number Publication Date
US3902497A true US3902497A (en) 1975-09-02

Family

ID=23804270

Family Applications (1)

Application Number Title Priority Date Filing Date
US454353A Expired - Lifetime US3902497A (en) 1974-03-25 1974-03-25 Body absorbable sponge and method of making

Country Status (9)

Country Link
US (1) US3902497A (en)
JP (1) JPS51116079A (en)
AR (1) AR205109A1 (en)
BR (1) BR7531268A (en)
CA (1) CA1045548A (en)
DE (1) DE2513159A1 (en)
FR (1) FR2265412B1 (en)
GB (1) GB1490425A (en)
IT (1) IT1050278B (en)

Cited By (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4128612A (en) * 1974-04-19 1978-12-05 American Cyanamid Company Making absorbable surgical felt
US4181983A (en) * 1977-08-29 1980-01-08 Kulkarni R K Assimilable hydrophilic prosthesis
US4186448A (en) * 1976-04-16 1980-02-05 Brekke John H Device and method for treating and healing a newly created bone void
US4744365A (en) * 1986-07-17 1988-05-17 United States Surgical Corporation Two-phase compositions for absorbable surgical devices
US4840626A (en) * 1986-09-29 1989-06-20 Johnson & Johnson Patient Care, Inc. Heparin-containing adhesion prevention barrier and process
US4968317A (en) * 1987-01-13 1990-11-06 Toermaelae Pertti Surgical materials and devices
US5124103A (en) * 1984-03-06 1992-06-23 United States Surgical Corporation Two phase compositions for absorbable surgical devices
US5354290A (en) * 1989-05-31 1994-10-11 Kimberly-Clark Corporation Porous structure of an absorbent polymer
US5403347A (en) * 1993-05-27 1995-04-04 United States Surgical Corporation Absorbable block copolymers and surgical articles fabricated therefrom
US5403870A (en) * 1989-05-31 1995-04-04 Kimberly-Clark Corporation Process for forming a porous particle of an absorbent polymer
US5431679A (en) * 1994-03-10 1995-07-11 United States Surgical Corporation Absorbable block copolymers and surgical articles fabricated therefrom
US5475063A (en) * 1991-02-12 1995-12-12 United States Surgical Corporation Blends of glycolide and/or lactide polymers and caprolactone and/or trimethylene carbonate polymers and absorbable surgical devices made
US5502092A (en) * 1994-02-18 1996-03-26 Minnesota Mining And Manufacturing Company Biocompatible porous matrix of bioabsorbable material
US5522841A (en) * 1993-05-27 1996-06-04 United States Surgical Corporation Absorbable block copolymers and surgical articles fabricated therefrom
US5567612A (en) * 1986-11-20 1996-10-22 Massachusetts Institute Of Technology Genitourinary cell-matrix structure for implantation into a human and a method of making
US5618313A (en) * 1994-10-11 1997-04-08 United States Surgical Corporation Absorbable polymer and surgical articles fabricated therefrom
EP0786259A2 (en) 1996-01-19 1997-07-30 United States Surgical Corporation Absorbable polymer blends and surgical articles fabricated therefrom
US5674286A (en) * 1991-02-12 1997-10-07 United States Surgical Corporation Bioabsorbable medical implants
US5709854A (en) * 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5716404A (en) * 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US5741685A (en) * 1995-06-07 1998-04-21 Children's Medical Center Corporation Parenchymal cells packaged in immunoprotective tissue for implantation
US5851833A (en) * 1991-10-24 1998-12-22 Children's Medical Center Corp. Neomorphogenesis of urological structures in vivo from cell culture
US5855610A (en) * 1995-05-19 1999-01-05 Children's Medical Center Corporation Engineering of strong, pliable tissues
US5904717A (en) * 1986-01-28 1999-05-18 Thm Biomedical, Inc. Method and device for reconstruction of articular cartilage
US5935127A (en) * 1997-12-17 1999-08-10 Biomet, Inc. Apparatus and method for treatment of a fracture in a long bone
US5935594A (en) * 1993-10-28 1999-08-10 Thm Biomedical, Inc. Process and device for treating and healing a tissue deficiency
US5948829A (en) * 1997-11-25 1999-09-07 Kimberly-Clark Worldwide, Inc. Process for preparing an absorbent foam
US5981825A (en) * 1994-05-13 1999-11-09 Thm Biomedical, Inc. Device and methods for in vivo culturing of diverse tissue cells
US5985434A (en) * 1997-11-25 1999-11-16 Kimberly-Clark Worldwide, Inc. Absorbent foam
US6007565A (en) * 1997-09-05 1999-12-28 United States Surgical Absorbable block copolymers and surgical articles fabricated therefrom
US6129761A (en) * 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US6191236B1 (en) 1996-10-11 2001-02-20 United States Surgical Corporation Bioabsorbable suture and method of its manufacture
US6206908B1 (en) 1994-09-16 2001-03-27 United States Surgical Corporation Absorbable polymer and surgical articles fabricated therefrom
US6228954B1 (en) 1991-02-12 2001-05-08 United States Surgical Corporation Blends of glycolide and/or lactide polymers and caprolactone and/or trimethylene carbonate polymers and absorabable surgical devices made therefrom
US6277927B1 (en) 1997-11-26 2001-08-21 United States Surgical Corporation Absorbable block copolymers and surgical articles fabricated therefrom
US6309635B1 (en) 1986-11-20 2001-10-30 Children's Medical Center Corp. Seeding parenchymal cells into compression resistant porous scaffold after vascularizing in vivo
US6546188B1 (en) 1998-01-16 2003-04-08 Sony Corporation Editing system and editing method
US20030152609A1 (en) * 2000-11-06 2003-08-14 Fischell Robert E. Devices and methods for reducing scar tissue formation
US20040058164A1 (en) * 1994-07-22 2004-03-25 Bennett Steven L. Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom
US20040121905A1 (en) * 2002-12-23 2004-06-24 Kimberly - Clark Worldwide, Inc Method of making an absorbent composite
US6783529B2 (en) 1999-04-09 2004-08-31 Depuy Orthopaedics, Inc. Non-metal inserts for bone support assembly
US6786908B2 (en) 1999-04-09 2004-09-07 Depuy Orthopaedics, Inc. Bone fracture support implant with non-metal spacers
US6808527B2 (en) 2000-04-10 2004-10-26 Depuy Orthopaedics, Inc. Intramedullary nail with snap-in window insert
US20040243043A1 (en) * 2002-06-14 2004-12-02 Mccarthy Simon J, Wound dressing and method for controlling severe, life-threatening bleeding
US6840962B1 (en) 1995-05-01 2005-01-11 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
US20050019262A1 (en) * 2003-07-25 2005-01-27 Rubicor Medical, Inc. Post-biopsy cavity treatment implants and methods
US20050038369A1 (en) * 2001-06-14 2005-02-17 Gregory Kenton W. Wound dressing and method for controlling severe, life-threatening bleeding
EP1547547A1 (en) 1994-05-13 2005-06-29 Kensey Nash Corporation Device and method for in vivo culturing of diverse tissue cells
US20050147656A1 (en) * 2001-06-14 2005-07-07 Hemcon, Inc. Tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan
US20050148963A1 (en) * 2004-01-05 2005-07-07 Brennan H. G. Bioabsorbable surgical sponge
WO2005062889A2 (en) * 2003-12-23 2005-07-14 Hemcon, Inc. Wound dressing and method for controlling severe, life- threatening bleeding
US20060004314A1 (en) * 2001-06-14 2006-01-05 Hemcon, Inc. Antimicrobial barriers, systems, and methods formed from hydrophilic polymer structures such as chistosan
US20060008419A1 (en) * 2003-01-09 2006-01-12 Polyganics B.V. Biomedical foams
US20060089584A1 (en) * 2001-06-14 2006-04-27 Mcadams Staci A Compositions, assemblies, and methods applied during or after a dental procedure to ameliorate fluid loss and/or promote healing, using a hydrophilic polymer sponge structure such as chistosan
US20060211973A1 (en) * 2005-03-17 2006-09-21 Gregory Kenton W Systems and methods for hemorrhage control and or tissue repair
US20070299339A1 (en) * 2003-07-25 2007-12-27 Rubicor Medical, Inc. Post-biopsy cavity treatment implants and methods
US7410488B2 (en) 2005-02-18 2008-08-12 Smith & Nephew, Inc. Hindfoot nail
US20080287907A1 (en) * 2006-05-23 2008-11-20 Providence Health System-Oregan D/B/A Providence St. Vincent Medical Center Systems and methods for introducing and applying a bandage structure within a body lumen or hollow body organ
US20090018479A1 (en) * 2002-06-14 2009-01-15 Hemcon Medical Technologies, Inc. Absorbable tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chistosan
EP2036582A1 (en) 1994-07-22 2009-03-18 United States Surgical Corporation Biobsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom
US7655009B2 (en) 2003-12-01 2010-02-02 Smith & Nephew, Inc. Humeral nail
US7744852B2 (en) 2003-07-25 2010-06-29 Rubicor Medical, Llc Methods and systems for marking post biopsy cavity sites
US20100168689A1 (en) * 2008-12-31 2010-07-01 Swain Larry D Systems for providing fluid flow to tissues
US20100172958A1 (en) * 2008-05-02 2010-07-08 Hemcon Medical Technologies, Inc. Wound dressing devices and methods
US8741335B2 (en) 2002-06-14 2014-06-03 Hemcon Medical Technologies, Inc. Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as Chitosan
WO2017050837A1 (en) 2015-09-23 2017-03-30 Novus Scientific Ab Three-dimensional medical implant for regeneration of soft tissue
US20180193010A1 (en) * 2017-01-06 2018-07-12 Ethicon, Inc. Scaffolds for implanting absorbable hemostats in field conditions
US10086105B2 (en) 2008-10-06 2018-10-02 Providence Health System—Oregon Chitosan foam medical devices and methods

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61149160A (en) * 1984-12-22 1986-07-07 株式会社 日本メデイカル・サプライ Biodegradable absorbable sponge and its production
DE4001833A1 (en) * 1990-01-23 1991-08-01 Juergen Dr Fischer Bleeding-prevention instrument in bone cavity - has small-volume implant expanded by fluid after insertion
DE4034921C2 (en) * 1990-11-01 1994-09-08 Kulicke Werner Michael Prof Dr Use of a moisture-storing, cotton-like plastic in upholstery and mattresses

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297033A (en) * 1963-10-31 1967-01-10 American Cyanamid Co Surgical sutures
US3666750A (en) * 1969-12-15 1972-05-30 Johnson & Johnson Hemostatic material
US3705585A (en) * 1971-07-15 1972-12-12 Dennis W Saffro Preformed surgical sponge
US3772136A (en) * 1971-04-20 1973-11-13 Gen Mills Inc Fibrous products from thermoplastic polyamide polymers
US3801675A (en) * 1970-02-20 1974-04-02 Johnson & Johnson Polymer blend containing polyacrylic acid,polyvinyl alcohol,and a polyacrylate
US3825007A (en) * 1972-01-07 1974-07-23 R Rand Pledgets

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297033A (en) * 1963-10-31 1967-01-10 American Cyanamid Co Surgical sutures
US3666750A (en) * 1969-12-15 1972-05-30 Johnson & Johnson Hemostatic material
US3801675A (en) * 1970-02-20 1974-04-02 Johnson & Johnson Polymer blend containing polyacrylic acid,polyvinyl alcohol,and a polyacrylate
US3772136A (en) * 1971-04-20 1973-11-13 Gen Mills Inc Fibrous products from thermoplastic polyamide polymers
US3705585A (en) * 1971-07-15 1972-12-12 Dennis W Saffro Preformed surgical sponge
US3825007A (en) * 1972-01-07 1974-07-23 R Rand Pledgets

Cited By (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4128612A (en) * 1974-04-19 1978-12-05 American Cyanamid Company Making absorbable surgical felt
US4186448A (en) * 1976-04-16 1980-02-05 Brekke John H Device and method for treating and healing a newly created bone void
US4181983A (en) * 1977-08-29 1980-01-08 Kulkarni R K Assimilable hydrophilic prosthesis
US5124103A (en) * 1984-03-06 1992-06-23 United States Surgical Corporation Two phase compositions for absorbable surgical devices
US5904717A (en) * 1986-01-28 1999-05-18 Thm Biomedical, Inc. Method and device for reconstruction of articular cartilage
US4744365A (en) * 1986-07-17 1988-05-17 United States Surgical Corporation Two-phase compositions for absorbable surgical devices
US4840626A (en) * 1986-09-29 1989-06-20 Johnson & Johnson Patient Care, Inc. Heparin-containing adhesion prevention barrier and process
US6309635B1 (en) 1986-11-20 2001-10-30 Children's Medical Center Corp. Seeding parenchymal cells into compression resistant porous scaffold after vascularizing in vivo
US5567612A (en) * 1986-11-20 1996-10-22 Massachusetts Institute Of Technology Genitourinary cell-matrix structure for implantation into a human and a method of making
US4968317A (en) * 1987-01-13 1990-11-06 Toermaelae Pertti Surgical materials and devices
US5354290A (en) * 1989-05-31 1994-10-11 Kimberly-Clark Corporation Porous structure of an absorbent polymer
US5403870A (en) * 1989-05-31 1995-04-04 Kimberly-Clark Corporation Process for forming a porous particle of an absorbent polymer
US5674286A (en) * 1991-02-12 1997-10-07 United States Surgical Corporation Bioabsorbable medical implants
US6228954B1 (en) 1991-02-12 2001-05-08 United States Surgical Corporation Blends of glycolide and/or lactide polymers and caprolactone and/or trimethylene carbonate polymers and absorabable surgical devices made therefrom
US5475063A (en) * 1991-02-12 1995-12-12 United States Surgical Corporation Blends of glycolide and/or lactide polymers and caprolactone and/or trimethylene carbonate polymers and absorbable surgical devices made
US5851833A (en) * 1991-10-24 1998-12-22 Children's Medical Center Corp. Neomorphogenesis of urological structures in vivo from cell culture
US20040170612A1 (en) * 1993-04-30 2004-09-02 Griffith Linda G. Injectable polysaccharide-cell compositions
US7807150B2 (en) 1993-04-30 2010-10-05 Massachusetts Institute Of Technology Injectable composition containing crosslinkable material and cells for forming animal tissue
US5709854A (en) * 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5554170A (en) * 1993-05-27 1996-09-10 United States Surgical Corporation Absorbable block copolymers and surgical articles fabricated therefrom
US5403347A (en) * 1993-05-27 1995-04-04 United States Surgical Corporation Absorbable block copolymers and surgical articles fabricated therefrom
US5522841A (en) * 1993-05-27 1996-06-04 United States Surgical Corporation Absorbable block copolymers and surgical articles fabricated therefrom
US5935594A (en) * 1993-10-28 1999-08-10 Thm Biomedical, Inc. Process and device for treating and healing a tissue deficiency
US5502092A (en) * 1994-02-18 1996-03-26 Minnesota Mining And Manufacturing Company Biocompatible porous matrix of bioabsorbable material
US5856367A (en) * 1994-02-18 1999-01-05 Minnesota Mining And Manufacturing Company Biocompatible porous matrix of bioabsorbable material
US5431679A (en) * 1994-03-10 1995-07-11 United States Surgical Corporation Absorbable block copolymers and surgical articles fabricated therefrom
US5981825A (en) * 1994-05-13 1999-11-09 Thm Biomedical, Inc. Device and methods for in vivo culturing of diverse tissue cells
EP1547547A1 (en) 1994-05-13 2005-06-29 Kensey Nash Corporation Device and method for in vivo culturing of diverse tissue cells
US6264701B1 (en) 1994-05-13 2001-07-24 Kensey Nash Corporation Device and methods for in vivo culturing of diverse tissue cells
US20040058164A1 (en) * 1994-07-22 2004-03-25 Bennett Steven L. Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom
EP2301597A1 (en) 1994-07-22 2011-03-30 United States Surgical Corporation Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom
US7321008B2 (en) 1994-07-22 2008-01-22 United States Surgical Corporation Bioabsorbable branched polymers end-capped with diketene acetals
EP2036582A1 (en) 1994-07-22 2009-03-18 United States Surgical Corporation Biobsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom
US20060293406A1 (en) * 1994-07-22 2006-12-28 Bennett Steven L Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom
US7097907B2 (en) 1994-07-22 2006-08-29 United States Surgical Corporation Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom
US20060014023A9 (en) * 1994-07-22 2006-01-19 Bennett Steven L Bioabsorbable branched polymers containing units derived from dioxanone and medical/surgical devices manufactured therefrom
US6206908B1 (en) 1994-09-16 2001-03-27 United States Surgical Corporation Absorbable polymer and surgical articles fabricated therefrom
US5618313A (en) * 1994-10-11 1997-04-08 United States Surgical Corporation Absorbable polymer and surgical articles fabricated therefrom
US5716404A (en) * 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US20050060033A1 (en) * 1995-05-01 2005-03-17 Vacanti Charles A. Tissue engineered tendons and ligaments
US7914579B2 (en) 1995-05-01 2011-03-29 Children's Medical Center Corporation Tissue engineered tendons and ligaments
US6840962B1 (en) 1995-05-01 2005-01-11 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
US20070005139A1 (en) * 1995-05-01 2007-01-04 Vacanti Charles A Tissue engineered tendons and ligaments
US6348069B1 (en) 1995-05-19 2002-02-19 Children's Medical Center Corporation Engineering of strong, pliable tissues
US5855610A (en) * 1995-05-19 1999-01-05 Children's Medical Center Corporation Engineering of strong, pliable tissues
USRE42479E1 (en) 1995-05-19 2011-06-21 Children's Medical Center Corporation Engineering of strong, pliable tissues
USRE42575E1 (en) 1995-05-19 2011-07-26 Children's Medical Center Corporation Engineering of strong, pliable tissues
US6129761A (en) * 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US5741685A (en) * 1995-06-07 1998-04-21 Children's Medical Center Corporation Parenchymal cells packaged in immunoprotective tissue for implantation
US5997568A (en) * 1996-01-19 1999-12-07 United States Surgical Corporation Absorbable polymer blends and surgical articles fabricated therefrom
EP0786259A2 (en) 1996-01-19 1997-07-30 United States Surgical Corporation Absorbable polymer blends and surgical articles fabricated therefrom
US6191236B1 (en) 1996-10-11 2001-02-20 United States Surgical Corporation Bioabsorbable suture and method of its manufacture
US6007565A (en) * 1997-09-05 1999-12-28 United States Surgical Absorbable block copolymers and surgical articles fabricated therefrom
US6136018A (en) * 1997-09-05 2000-10-24 United States Surgical Corporation Absorbable block copolymers and surgical articles fabricated therefrom
US5985434A (en) * 1997-11-25 1999-11-16 Kimberly-Clark Worldwide, Inc. Absorbent foam
US5948829A (en) * 1997-11-25 1999-09-07 Kimberly-Clark Worldwide, Inc. Process for preparing an absorbent foam
US6277927B1 (en) 1997-11-26 2001-08-21 United States Surgical Corporation Absorbable block copolymers and surgical articles fabricated therefrom
US5935127A (en) * 1997-12-17 1999-08-10 Biomet, Inc. Apparatus and method for treatment of a fracture in a long bone
US6546188B1 (en) 1998-01-16 2003-04-08 Sony Corporation Editing system and editing method
US6786908B2 (en) 1999-04-09 2004-09-07 Depuy Orthopaedics, Inc. Bone fracture support implant with non-metal spacers
US6783529B2 (en) 1999-04-09 2004-08-31 Depuy Orthopaedics, Inc. Non-metal inserts for bone support assembly
US6808527B2 (en) 2000-04-10 2004-10-26 Depuy Orthopaedics, Inc. Intramedullary nail with snap-in window insert
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
US20030152609A1 (en) * 2000-11-06 2003-08-14 Fischell Robert E. Devices and methods for reducing scar tissue formation
US7482503B2 (en) 2001-06-14 2009-01-27 Providence Health System-Oregon Wound dressing and method for controlling severe, life-threatening bleeding
US20060089584A1 (en) * 2001-06-14 2006-04-27 Mcadams Staci A Compositions, assemblies, and methods applied during or after a dental procedure to ameliorate fluid loss and/or promote healing, using a hydrophilic polymer sponge structure such as chistosan
US20050038369A1 (en) * 2001-06-14 2005-02-17 Gregory Kenton W. Wound dressing and method for controlling severe, life-threatening bleeding
US7897832B2 (en) 2001-06-14 2011-03-01 Hemcon Medical Technologies, Inc. Compositions, assemblies, and methods applied during or after a dental procedure to ameliorate fluid loss and/or promote healing, using a hydrophilic polymer sponge structure such as chitosan
US20110143312A1 (en) * 2001-06-14 2011-06-16 Hemcon Medical Technologies, Inc. Compositions, assemblies, and methods applied during or after a dental procedure to ameliorate fluid loss and/or promote healing, using a hydrophilic polymer sponge structure such as chitosan
US20050147656A1 (en) * 2001-06-14 2005-07-07 Hemcon, Inc. Tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan
US9132206B2 (en) 2001-06-14 2015-09-15 Hemcon Medical Technologies, Inc. Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as chitosan
US9004918B2 (en) 2001-06-14 2015-04-14 Hemcon Medical Technologies, Inc. Compositions, assemblies, and methods applied during or after a dental procedure to ameliorate fluid loss and/or promote healing, using a hydrophilic polymer sponge structure such as chitosan
US20060004314A1 (en) * 2001-06-14 2006-01-05 Hemcon, Inc. Antimicrobial barriers, systems, and methods formed from hydrophilic polymer structures such as chistosan
US7820872B2 (en) 2001-06-14 2010-10-26 Providence Health System-Oregon Wound dressings, apparatus, and methods for controlling severe, life-threatening bleeding
US20080213344A1 (en) * 2002-06-14 2008-09-04 Providence Health System- Oregon Wound dressing and method for controlling severe, life-threatening bleeding
US20080146984A1 (en) * 2002-06-14 2008-06-19 Hemcon Medical Technologies, Inc. Method for preparing a compressed wound dressing
US8668924B2 (en) 2002-06-14 2014-03-11 Providence Health System—Oregon Wound dressing and method for controlling severe, life-threatening bleeding
US8741335B2 (en) 2002-06-14 2014-06-03 Hemcon Medical Technologies, Inc. Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as Chitosan
US8313474B2 (en) 2002-06-14 2012-11-20 Hemcon Medical Technologies, Inc. Method for preparing a compressed wound dressing
US20090018479A1 (en) * 2002-06-14 2009-01-15 Hemcon Medical Technologies, Inc. Absorbable tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chistosan
US7371403B2 (en) 2002-06-14 2008-05-13 Providence Health System-Oregon Wound dressing and method for controlling severe, life-threatening bleeding
US20040243043A1 (en) * 2002-06-14 2004-12-02 Mccarthy Simon J, Wound dressing and method for controlling severe, life-threatening bleeding
US8269058B2 (en) 2002-06-14 2012-09-18 Hemcon Medical Technologies, Inc. Absorbable tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan
US20040121905A1 (en) * 2002-12-23 2004-06-24 Kimberly - Clark Worldwide, Inc Method of making an absorbent composite
US6863924B2 (en) 2002-12-23 2005-03-08 Kimberly-Clark Worldwide, Inc. Method of making an absorbent composite
US11911524B2 (en) 2003-01-09 2024-02-27 Stryker European Operations Holdings Llc Biomedical foams
US20060008419A1 (en) * 2003-01-09 2006-01-12 Polyganics B.V. Biomedical foams
US11147898B2 (en) 2003-01-09 2021-10-19 Stryker European Operations Holdings Llc Biomedical foams
US9610377B2 (en) 2003-01-09 2017-04-04 Stryker European Holdings I, Llc Biomedical foams
US10507260B2 (en) 2003-01-09 2019-12-17 Stryker European Holdings I, Llc Biomedical foams
US20070299339A1 (en) * 2003-07-25 2007-12-27 Rubicor Medical, Inc. Post-biopsy cavity treatment implants and methods
US8491630B2 (en) 2003-07-25 2013-07-23 Encapsule Medical, LLC. Post-biopsy cavity treatment implants and methods
US20070299541A1 (en) * 2003-07-25 2007-12-27 Rubicor Medical, Inc. Post-biopsy cavity treatment implants and methods
US20050019262A1 (en) * 2003-07-25 2005-01-27 Rubicor Medical, Inc. Post-biopsy cavity treatment implants and methods
US7744852B2 (en) 2003-07-25 2010-06-29 Rubicor Medical, Llc Methods and systems for marking post biopsy cavity sites
US7780948B2 (en) 2003-07-25 2010-08-24 Rubicor Medical, Llc Post biopsy cavity treatment implants and methods
US7537788B2 (en) 2003-07-25 2009-05-26 Rubicor Medical, Inc. Post-biopsy cavity treatment implants and methods
US8092779B2 (en) 2003-07-25 2012-01-10 Rubicor Medical, Llc Post-biopsy cavity treatment implants and methods
US20080114329A1 (en) * 2003-10-16 2008-05-15 Rubicor Medical, Inc. Post-biopsy cavity treatment implants and methods
US7534452B2 (en) 2003-10-16 2009-05-19 Rubicor Medical, Inc. Post-biopsy cavity treatment implants and methods
US7655009B2 (en) 2003-12-01 2010-02-02 Smith & Nephew, Inc. Humeral nail
WO2005062889A2 (en) * 2003-12-23 2005-07-14 Hemcon, Inc. Wound dressing and method for controlling severe, life- threatening bleeding
US8951565B2 (en) 2003-12-23 2015-02-10 Hemcon Medical Technologies, Inc. Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as chitosan
WO2005062889A3 (en) * 2003-12-23 2006-04-20 Hemcon Inc Wound dressing and method for controlling severe, life- threatening bleeding
US20050148963A1 (en) * 2004-01-05 2005-07-07 Brennan H. G. Bioabsorbable surgical sponge
US7410488B2 (en) 2005-02-18 2008-08-12 Smith & Nephew, Inc. Hindfoot nail
USRE46078E1 (en) 2005-02-18 2016-07-26 Smith & Nephew, Inc. Hindfoot nail
USRE46008E1 (en) 2005-02-18 2016-05-24 Smith & Nephew, Inc. Hindfoot nail
USRE44501E1 (en) 2005-02-18 2013-09-17 Smith & Nephew, Inc. Hindfoot nail
US20060211973A1 (en) * 2005-03-17 2006-09-21 Gregory Kenton W Systems and methods for hemorrhage control and or tissue repair
US9204957B2 (en) 2005-03-17 2015-12-08 Hemcon Medical Technologies, Inc. Systems and methods for hemorrhage control and or tissue repair
US20080287907A1 (en) * 2006-05-23 2008-11-20 Providence Health System-Oregan D/B/A Providence St. Vincent Medical Center Systems and methods for introducing and applying a bandage structure within a body lumen or hollow body organ
US8920514B2 (en) 2006-05-23 2014-12-30 Providence Health System—Oregon Systems and methods for introducing and applying a bandage structure within a body lumen or hollow body organ
US9205170B2 (en) 2008-05-02 2015-12-08 Hemcon Medical Technologies, Inc. Wound dressing devices and methods
US20100172958A1 (en) * 2008-05-02 2010-07-08 Hemcon Medical Technologies, Inc. Wound dressing devices and methods
US10086105B2 (en) 2008-10-06 2018-10-02 Providence Health System—Oregon Chitosan foam medical devices and methods
US9918880B2 (en) 2008-12-31 2018-03-20 Kci Licensing, Inc. Systems for providing fluid flow to tissues
CN102264432B (en) * 2008-12-31 2013-10-23 凯希特许有限公司 Systems for providing fluid flow to tissues
AU2009335032B2 (en) * 2008-12-31 2015-08-27 3M Innovative Properties Company Systems for providing fluid flow to tissues
CN102264432A (en) * 2008-12-31 2011-11-30 凯希特许有限公司 Systems for providing fluid flow to tissues
US20100168689A1 (en) * 2008-12-31 2010-07-01 Swain Larry D Systems for providing fluid flow to tissues
US8734409B2 (en) * 2008-12-31 2014-05-27 Kci Licensing, Inc. Systems for providing fluid flow to tissues
WO2017050837A1 (en) 2015-09-23 2017-03-30 Novus Scientific Ab Three-dimensional medical implant for regeneration of soft tissue
US10722336B2 (en) 2015-09-23 2020-07-28 Novus Scientific Ab Three-dimensional medical implant
US11471258B2 (en) 2015-09-23 2022-10-18 Novus Scientific Ab Three-dimensional medical implant
US20180193010A1 (en) * 2017-01-06 2018-07-12 Ethicon, Inc. Scaffolds for implanting absorbable hemostats in field conditions
US11254061B2 (en) * 2017-01-06 2022-02-22 Ethicon, Inc. Scaffolds for implanting absorbable hemostats in field conditions

Also Published As

Publication number Publication date
FR2265412B1 (en) 1978-10-06
GB1490425A (en) 1977-11-02
IT1050278B (en) 1981-03-10
DE2513159A1 (en) 1975-10-09
JPS51116079A (en) 1976-10-13
BR7531268A (en) 1975-12-23
AU7822275A (en) 1976-08-19
CA1045548A (en) 1979-01-02
FR2265412A1 (en) 1975-10-24
AR205109A1 (en) 1976-04-05

Similar Documents

Publication Publication Date Title
US3902497A (en) Body absorbable sponge and method of making
US3988411A (en) Spinning and shaping poly-(N-acetyl-D-glucosamine)
US4074366A (en) Poly(N-acetyl-D-glucosamine) products
US3937223A (en) Compacted surgical hemostatic felt
Qin The gel swelling properties of alginate fibers and their applications in wound management
US4524064A (en) Wound-covering materials
EP0815879B1 (en) Bioabsorbable medical devices from oxidized polysaccharides
AU2003204986B2 (en) Hemostatic wound dressing and method of making same
JP5638521B2 (en) Healing wound dressing that reduces temperature
EP0265906A2 (en) Wound dressing
US3989535A (en) Solution of poly(N-acetyl-D-glucosamine)
US20030073663A1 (en) Bioabsorbable medical devices from oxidized polysaccharides
KR20040047537A (en) Hemostatic wound dressing containing aldehyde-modified polysaccharide
EP1481694A1 (en) Biodegradable hemostatic wound dressings
NZ206488A (en) Liquid-loaded medical pad with microbially-produced cellulose
KR100748348B1 (en) Method for the preparation of hydrogels for wound dressing using radiation irradiation
KR101735899B1 (en) Biodegradable non-woven material for medical purposes
CA2155518A1 (en) Pharmaceutical compositions comprising a spongy material consisting of ester derivatives of hyarulonic acid combined with other pharmacologically active substances
Chen et al. Vapor-phase glutaraldehyde crosslinked waste protein-based nanofiber nonwovens as an environmentally friendly wound dressing
NO833768L (en) ABSORBABLE HEMOSTATIC MATERIAL.
KR100546793B1 (en) Foam dressing using chitosan and Method of preparing the same
US20020028232A1 (en) Wound dressing
WO2001091681A1 (en) Wound dressing
JPH0442020B2 (en)
KR100372560B1 (en) Charcoal filled hydrogels dressings and process for preparing thereof by irradiation